- likes
- 43
- comments
- 0
Post
Caris Life Sciences announced that the first patients have been enrolled in a prospective, real-world observational study evaluating Caris ChromoSeq™, a Whole Genome Sequencing (WGS) assay designed to provide comprehensive genomic characterization of myeloid malignancies through a single integrated workflow. "Oncology has embraced comprehensive molecular profiling, yet patients with myeloid malignancies are often still evaluated through a fragmented testing process that requires multiple assays and workflows. Caris ChromoSeq was developed to challenge that paradigm,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. Learn more: https://ow.ly/jvS85105CR4